Axsome Therapeutics, Inc. Q3 2025 Earnings Recap

AXSM Q3 2025 November 5, 2025

Axsome Therapeutics reported robust Q3 2025 results, with total revenue rising 63% year-over-year to $171 million, driven by strong demand for AUVELITY and steady growth of SUNOSI.

Earnings Per Share Miss

$-0.94 vs $-0.82 est.

-14.6% surprise

Revenue Miss

170992000 vs 191333990 est.

-10.6% surprise

Market Reaction

1-Day +0.56%

5-Day +2.13%

30-Day +12.28%

Key Takeaways

AUVELITY sales reached $136.1 million, a 69% increase year-over-year, reflecting strong market traction.
SUNOSI revenues grew 35% year-over-year to $32.8 million, demonstrating ongoing commercial momentum.
Axsome submitted a supplemental NDA for AXS-05 in Alzheimer's disease agitation and plans to initiate multiple Phase III trials across ADHD and narcolepsy.
The company is well-positioned with a deep late-stage pipeline and a diverse portfolio of therapies addressing significant unmet needs in CNS health.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit AXSM on AllInvestView.